Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 11/20 | 0.52 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.42 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3428105 | 0.89 | CHRNA7 (0.58) | EPHX2CHRNA7CYP2C9CYP2C19CYP2J2 | |
| SCHEMBL3401931 | 0.77 | ALDH1A1 (0.57) | EPHX2TRPV1KLKB1 | |
| SCHEMBL3425865 | 0.77 | CHRNA7 (0.56) | EPHX2CHRNA7CYP2C9CYP2C19CYP2J2 | |
| SCHEMBL7987284 | 0.76 | EPHX2 (0.56) | EPHX2CHRNA7CYP2C9CYP2C19CYP2J2 | |
| SCHEMBL15350075 | 0.75 | EPHX2 (0.55) | EPHX2CYP2C9CYP2C19CYP2J2L3MBTL1 | |
| SCHEMBL15351096 | 0.74 | EPHX2 (0.59) | EPHX2CYP2C9CYP2C19CYP2J2L3MBTL1 | |
| SCHEMBL13876156 | 0.74 | EPHX2 (0.81) | EPHX2CYP2C9CYP2C19CYP2J2L3MBTL1 | |
| SCHEMBL3426508 | 0.74 | EPHX2 (0.56) | EPHX2CHRNA7CYP2C9CYP2C19CYP2J2 | |
| SCHEMBL3399338 | 0.73 | PRKAB2 (0.65) | EPHX2CYP2C9CYP2C19CYP2J2L3MBTL1 | |
| SCHEMBL13702303 | 0.73 | L3MBTL1 (0.65) | EPHX2CYP2C9CYP2C19CYP2J2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2250162-B1 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2014-03-19 | — | — | EP | claimed |
| US-8536221-B2 | Amide derivatives as positive allosteric modulators and methods of use thereof | ABBVIE INC. (US) | 2013-09-17 | — | — | US | claimed |
| US-20090270408-A1 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-10-29 | — | — | US | claimed |
| EP-2250162-B1 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2014-03-19 | — | — | EP | disclosed |
| US-8536221-B2 | Amide derivatives as positive allosteric modulators and methods of use thereof | ABBVIE INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-20090270408-A1 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270408-A1 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | CHRNA2, CHRNA4, CHRNA5 | EPHX2 3581/4885CHRNA7 8/4885CYP2C9 4689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.